CLINICAL_TRIALS
research
· 2026-03-03
Clinical Trial Update: A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC [Phase 2]
Summary
A Phase 2, open-label, randomized, multicenter study evaluating different dosing regimens of tarlatamab in patients with small cell lung cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Small Cell Lung Cancer (SCLC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING